Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · IEX Real-Time Price · USD
3.220
-0.040 (-1.23%)
At close: Jul 2, 2024, 4:00 PM
3.290
+0.070 (2.17%)
After-hours: Jul 2, 2024, 6:42 PM EDT
Fate Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Fate Therapeutics stock have an average target of 6.85, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 112.73% from the current stock price of 3.22.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for FATE stock from 15 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 9 | 9 | 10 | 10 | 9 | 9 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 14 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $4 → $6 | Hold → Buy | Upgrades | $4 → $6 | +86.34% | Jun 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +55.28% | May 16, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +179.50% | May 10, 2024 |
| BMO Capital | BMO Capital | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +86.34% | May 10, 2024 |
| Wedbush | Wedbush | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +55.28% | May 10, 2024 |
Financial Forecast
Revenue This Year
4.72M
from 63.53M
Decreased by -92.56%
Revenue Next Year
3.45M
from 4.72M
Decreased by -26.88%
EPS This Year
-1.94
from -1.64
EPS Next Year
-1.89
from -1.94
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9.4M | 21.0M | 21.0M | 29.0M | 105.0M |
| Avg | 4.7M | 3.5M | 4.9M | 16.2M | 90.0M |
| Low | 1.9M | n/a | n/a | n/a | 74.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -85.3% | 344.5% | 508.0% | 496.9% | 548.8% |
| Avg | -92.6% | -26.9% | 40.6% | 233.3% | 455.9% |
| Low | -97.0% | - | - | - | 362.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.37 | -0.92 | -1.11 | -1.06 | -0.95 |
| Avg | -1.94 | -1.89 | -1.59 | -1.08 | -0.92 |
| Low | -2.57 | -2.41 | -2.21 | -1.08 | -0.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.